Targeting the BH3-interacting domain death agonist to develop mechanistically unique antidepressants
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
The BH3-interacting domain death agonist (Bid) is a pro-apoptotic member of the B-cell lymphoma-2 (Bcl-2) protein family. Previous studies have shown that stress reduces levels of Bcl-2 in brain regions implicated in the pathophysiology of mood disorders, whereas antidepressants and mood stabilizers increase Bcl-2 levels. The Bcl-2 protein family has an essential role in cellular resilience as well as synaptic and neuronal plasticity and may influence mood and affective behaviors. This study inhibited Bid in mice using two pharmacological antagonists (BI-11A7 and BI-2A7); the selective serotonin reuptake inhibitor citalopram was used as a positive control. These agents were studied in several well-known rodent models of depression—the forced swim test (FST), the tail suspension test (TST), and the learned helplessness (LH) paradigm—as well as in the female urine sniffing test (FUST), a measure of sex-related reward-seeking behavior. Citalopram and BI-11A7 both significantly reduced immobility time in the FST and TST and attenuated escape latencies in mice that underwent the LH paradigm. In the FUST, both agents significantly improved duration of female urine sniffing in mice that had developed helplessness. LH induction increased the activation of apoptosis-inducing factor (AIF), a caspase-independent cell death constituent activated by Bid, and mitochondrial AIF expression was attenuated by chronic BI-11A7 infusion. Taken together, the results suggest that functional perturbation of apoptotic proteins such as Bid and, alternatively, enhancement of Bcl-2 function, is a putative strategy for developing novel therapeutics for mood disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Belmaker, R. H., & Agam, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra073096 · Cited by 2,166
Excess mortality of mental disorder
Harris, C., & Barraclough, B. (1998) · British Journal of Psychiatry · doi:10.1192/bjp.173.1.11 · Cited by 1,881
Assessing antidepressant activity in rodents: recent developments and future needs
Cryan, J. F., Markou, A., & Lucki, I. (2002) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(02)02017-5 · Cited by 1,551
The cellular neurobiology of depression
Manji, H. K., Drevets, W. C., & Charney, D. S. (2001) · Nature Medicine · doi:10.1038/87865 · Cited by 1,182
Self-citationMaeng, S., Zarate, C. A., Du, J., Schloesser, R. J., McCammon, J., Chen, G., & Manji, H. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.028 · Cited by 1,103
Self-citationBid-deficient mice are resistant to Fas-induced hepatocellular apoptosis
Yin, X.-M., Wang, K., Gross, A., Zhao, Y., Zinkel, S., Klocke, B., Roth, K. A., & Korsmeyer, S. J. (1999) · Nature · doi:10.1038/23730 · Cited by 1,004
Mortality of patients with mood disorders: follow-up over 34–38 years
Angst, F., Stassen, H. H., Clayton, P. J., & Angst, J. (2002) · Journal of Affective Disorders · doi:10.1016/s0165-0327(01)00377-9 · Cited by 881
Cryan, J. F., & Mombereau, C. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001457 · Cited by 616
Awareness, diagnosis, and treatment of depression
the Council on Scientific Affairs, A. M. A., Goldman, L. S., Nielsen, N. H., & Champion, H. C. (1999) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.1999.03478.x · Cited by 466
Hiroeh, U., Appleby, L., Mortensen, P. B., & Dunn, G. (2001) · The Lancet · doi:10.1016/s0140-6736(01)07216-6 · Cited by 327
Cited by
Liang, S., Wang, T., Hu, X., Luo, J., Li, W., Wu, X., Duan, Y., & Jin, F. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.09.033 · Cited by 651
Impaired mitochondrial function in psychiatric disorders
Manji, H., Kato, T., Di Prospero, N. A., Ness, S., Beal, M. F., Krams, M., & Chen, G. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3229 · Cited by 483
Self-citationCell atrophy and loss in depression: reversal by antidepressant treatment
Banasr, M., Dwyer, J. M., & Duman, R. S. (2011) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2011.09.002 · Cited by 201
Discovery and validation of blood biomarkers for suicidality
Le-Niculescu, H., Levey, D. F., Ayalew, M., Palmer, L., Gavrin, L. M., Jain, N., Winiger, E., Bhosrekar, S., Shankar, G., Radel, M., et al. (2013) · Molecular Psychiatry · doi:10.1038/mp.2013.95 · Cited by 193
The role of mitochondria in mood disorders: from physiology to pathophysiology and to treatment
Giménez-Palomo, A., Dodd, S., Anmella, G., Carvalho, A. F., Scaini, G., Quevedo, J., Pacchiarotti, I., Vieta, E., & Berk, M. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.546801 · Cited by 140
“In patients treated with antidepressants, there is an increase in the levels of BDNF mRNA (260) and a reversion of the decrease in CREB levels seen in patients with depression (261), which could be mechanisms of action in mood disorders (262).”
Background
Metadata
- Authors
- Malkesman, O., Austin, D. R., Tragon, T., Henter, I. D., Reed, J. C., Pellecchia, M., Chen, G., & Manji, H. K.
- Venue
- Molecular Psychiatry
- Published
- 2011-07-05
- Volume
- 17
- Issue
- 8
- Pages
- 770-780
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- OpenAlex
- W2087004329
- Cited by
- 29
- References
- 14
- FWCI
- 2.29
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting the BH3-interacting domain death agonist to develop mechanistically unique antidepressants. https://app.cochat.ai/papers/10.1038/mp.2011.77
- The paper
- Malkesman, O., Austin, D. R., Tragon, T., Henter, I. D., Reed, J. C., Pellecchia, M., Chen, G., & Manji, H. K. (2012). Targeting the BH3-interacting domain death agonist to develop mechanistically unique antidepressants. Molecular Psychiatry. https://doi.org/10.1038/mp.2011.77
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.